[Abnormalities of the erythropoiesis at the beginning of remission in acute promyelocytic leukemia treated with arabinoside-cytosine].
D000741:Anemia, Aplastic / Q000188:drug therapy; D001856:Bone Marrow Examination; D002467:Cell Nucleus / Q000187:drug effects; D002648:Child; D003561:Cytarabine / Q000627:therapeutic use*; D004912:Erythrocytes / Q000187:drug effects; D004920:Erythropoiesis / Q000187:drug effects*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000097:blood / Q000188:drug therapy*; D008297:Male; D008533:Megakaryocytes / Q000187:drug effects; D008727:Methotrexate / Q000627:therapeutic use; D008938:Mitosis / Q000187:drug effects; D012156:Reticulocytes / Q000187:drug effects; D013866:Thioguanine / Q000627:therapeutic use
D003561:Cytarabine; D013866:Thioguanine; D008727:Methotrexate
Anomalies de l'érythropoïèse lors de l'installation de la rémission dans la leucémie promyélocytaire aiguë traitée par l'arabinoside-cytosine.